Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Liverpool University Hospitals NHS Foundation Trust
282 participants
Oct 13, 2023
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to assess a new test to detect antibodies which may form following kidney transplant. These antibodies can be difficult to detect as they do not cause any symptoms but can lead to kidney damage. A new blood test will be performed alongside existing antibody tests to see how well the test functions in comparison and to see how well it is able to distinguish between inflammation caused by antibodies and other sorts of inflammation such as a urinary tract infection. The investigators also want to determine whether it is predictable whom will develop antibodies after a transplant and use these results to change the current way patients are monitored for antibodies after receiving a transplant. In addition to this, the investigators want to establish if patients over 60 years of age are relatively protected against immunological events such as rejection compared to patients who are under 60 years of age. The results could potentially lead to using a different immunosuppression regime based on which population age group patients belong to and lowering the risks associated with these drugs.
Eligibility
Inclusion Criteria10
- cf-DNA arm:
- Adult patients transplanted within 6-12 months (retrospective recruitment)
- Patients admitted for renal transplant or within the first 6 months following transplant (prospective recruitment)
- Patients must have capacity to provide informed consent
- Patients must have received a high-risk transplant defined as level 4 mismatch, cRF \>20, second or subsequent transplant, ABO or HLA incompatible
- Older Age Immunological Events:
- \- Any adult patient with capacity undergoing, or within 72 hours of, a renal transplant
- Predictive models:
- Any adult patient with capacity undergoing, or within 72 hours of, a renal transplant
- Unsensitized pre-transplant
Exclusion Criteria11
- cf-DNA arm:
- Transplanted for longer than 12 months;
- Low risk transplants;
- Patients lacking capacity;
- Older Age Immunological Events:
- Patients lacking capacity
- Patients transplanted longer than 2 weeks
- Predictive models:
- Sensitised patients
- Patients lacking capacity
- Patients transplanted longer than 2 weeks
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
In addition to the standard of care tests, participants will have an additional blood sample (dd-cf DNA). A cohort study patients who have undergone high immunological risk kidney transplant at our centre defined as a re-transplant, where the cRF is \>20% or where there is a level 4 HLA-mismatch. We will take a single plasma sample for dd-cfDNA testing at 6-12 months post-transplant and pair this with an assessment of renal function (creatinine, eGFR), MSU, BK and CMV PCR, single antigen bead (SAB) monitoring of HLA-specific antibodies and allograft USS.
Determine the overall frequency of immunological events and de novo HLA specific antibody formation in the \<60 and \>60 age population. Standard of care test taken at the different time intervals for routine storage. We will use those samples for HLA testing (either screening alone or screening and single antigen bead testing if screening yields a positive result).
A machine learning model will be developed in Python using a range of pre- and post-transplant variables to determine a predictive model for de novo HLA-specific antibody following renal transplant.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06025240